HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Budget Increases For OTC Drugs, Supplements Survive 2004 Process

This article was originally published in The Tan Sheet

Executive Summary

Funding increases for OTC drug and dietary supplement activities at FDA are likely to see increased support from the Bush administration and Congress as the fiscal year 2005 budget process kicks off

You may also be interested in...



FDA 2005 Budget Request Omits Boost For OTCs, Asks For CDER FTE Cutbacks

FDA's fiscal 2005 budget request provides no new increase for over-the-counter drug activities

McClellan Cites OTC Relief For States With Tightened Budget Belts

FDA Commissioner Mark McClellan, MD/PhD, highlighted the cost-effectiveness of OTC drugs in reducing pricing pressures on the healthcare system at an Academy Health/Health Affairs National Health Policy Conference Jan. 28

FDA Announces “Proactive” Approach To Rx-To-OTC Switches

FDA plans to take a more active role in initiating Rx-to OTC switches in coming years, Senior Associate Commissioner for Management & Systems Jeff Weber said Feb. 3

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS128272

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel